Literature DB >> 16517694

Mechanisms of immunopathology in murine models of central nervous system demyelinating disease.

Anne M Ercolini1, Stephen D Miller.   

Abstract

Many disorders of the CNS, such as multiple sclerosis (MS), are characterized by the loss of the myelin sheath surrounding nerve axons. MS is associated with infiltration of inflammatory cells into the brain and spinal cord, which may be the primary cause of demyelination or which may be induced secondary to axonal damage. Both the innate and adaptive arms of the immune system have been reported to play important roles in myelin destruction. Numerous murine demyelinating models, both virus-induced and/or autoimmune, are available, which reflect the clinical and pathological variability seen in human disease. This review will discuss the immunopathologic mechanisms involved in these demyelinating disease models.

Entities:  

Mesh:

Year:  2006        PMID: 16517694     DOI: 10.4049/jimmunol.176.6.3293

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

Review 1.  Innate immunity in the central nervous system.

Authors:  Richard M Ransohoff; Melissa A Brown
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

2.  Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells.

Authors:  Leah M Alabanza; Naomi L Esmon; Charles T Esmon; Margaret S Bynoe
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

3.  Expression of HERV-Fc1, a human endogenous retrovirus, is increased in patients with active multiple sclerosis.

Authors:  Magdalena Janina Laska; Tomasz Brudek; Kari Konstantin Nissen; Tove Christensen; Anné Møller-Larsen; Thor Petersen; Bjørn Andersen Nexø
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

Review 4.  Laminin isoforms in development and disease.

Authors:  Susanne Schéele; Alexander Nyström; Madeleine Durbeej; Jan F Talts; Marja Ekblom; Peter Ekblom
Journal:  J Mol Med (Berl)       Date:  2007-04-11       Impact factor: 4.599

5.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

6.  Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation.

Authors:  Roberta Brambilla; Trikaldarshi Persaud; Xianchen Hu; Shaffiat Karmally; Valery I Shestopalov; Galina Dvoriantchikova; Dmitry Ivanov; Lubov Nathanson; Scott R Barnum; John R Bethea
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 7.  CD4 T cells in immunity and immunotherapy of Alzheimer's disease.

Authors:  Alon Monsonego; Anna Nemirovsky; Idan Harpaz
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

8.  T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease.

Authors:  Yair Fisher; Anna Nemirovsky; Rona Baron; Alon Monsonego
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

9.  CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination.

Authors:  Charles L Howe; Daren Ure; Jaimie D Adelson; Reghann LaFrance-Corey; Aaron Johnson; Moses Rodriguez
Journal:  J Neuroimmunol       Date:  2007-05-09       Impact factor: 3.478

Review 10.  Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS.

Authors:  Gabriel A Silva
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.